In a clinical study, non-small-cell lung carcinoma (NSCLC) patients treated with PD-1 blockade (pembrolizumab), the ones with more CD8+ T-cell infiltration have a durable response, whereas in advanced patients, CD8+ T cells are at a rejected state. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.